This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
BMC Cancer Open Access 03 November 2023
-
Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma
Nature Cancer Open Access 20 April 2023
-
BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia
Cell Death Discovery Open Access 15 November 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Letai AG . Diagnosing and exploiting cancer’s addiction to blocks in apoptosis. Nat Rev Cancer 2008; 8: 121–132.
Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351–365.
BCL-2 inhibitor yields high response in CLL and SLL. Cancer Discov 2014; 4: OF5.
Davids MS, Roberts AW, Anderson MA, Pagel JM, Kahl BS, Gerecitano JF et al. The BCL-2-specific BH3-mimetic ABT-199 (GDC-0199) Is active and well-tolerated in patients with relapsed Non-Hodgkin lymphoma: interim results of a Phase I study. ASH Annu Meet Abstr 2012; 120: 304.
Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202–208.
Foight GW, Ryan JA, Gullá SV, Letai A, Keating AE . Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells. ACS Chem Biol 2014; 9: 1962–1968.
Munshi NC, Hideshima T, Carrasco D, Shammas M, Auclair D, Davies F et al. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 2004; 103: 1799–1806.
Wuillème-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005; 19: 1248–1252.
Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol Off J Am Soc Clin Oncol 2012; 30: 488–496.
Bodet L, Gomez-Bougie P, Touzeau C, Dousset C, Descamps G, Maïga S et al. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood 2011; 118: 3901–3910.
Touzeau C, Dousset C, Le Gouill S, Sampath D, Leverson JD, Souers AJ et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia 2013; 28: 210–212.
Morales AA, Kurtoglu M, Matulis SM, Liu J, Siefker D, Gutman DM et al. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. Blood 2011; 118: 1329–1339.
Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 2014; 4: 362–375.
Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov 2014; 4: 1074–1087.
Kumar S, Vij R, Kaufman J, Mikhael J, Facon T, Moreau P et alPhase I Interim Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/refractory Multiple Myeloma. J Clin Oncol 2015; 33 (suppl: abstract 8576)..
Touzeau C, Chanan-Khan A, Roberts AW, Agarwal A, Facon T, Lebovic D et alPhase 1b Interim Results: Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma. J Clin Oncol 2015; 33 (suppl): abstract 8580..
Ryan J, Letai A . BH3 profiling in whole cells by fluorimeter or FACS. Methods 2013; 61: 156–164.
Acknowledgements
We gratefully acknowledge support from NIH grants R01CA129974. CT was supported by the Fondation Française pour la Recherche contre le Myélome et les Gammapathies monoclonales (F.F.R.M.G.).
Author contributions
AL and CT designed the research and wrote the manuscript. CT performed the experiments. CT, AL, JR, TNC analyzed the data. PR, KA, MA, SLG and PM provided myeloma cells. All the authors critically reviewed the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
AL has been a paid advisor to AbbVie. AL’s laboratory has received sponsorship for research with AbbVie.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Touzeau, C., Ryan, J., Guerriero, J. et al. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia 30, 761–764 (2016). https://doi.org/10.1038/leu.2015.184
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.184
This article is cited by
-
Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
BMC Cancer (2023)
-
Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma
Nature Cancer (2023)
-
Mitochondrial dysfunction and drug targets in multiple myeloma
Journal of Cancer Research and Clinical Oncology (2023)
-
Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination
Journal of Hematology & Oncology (2022)
-
Single-cell profiling of tumour evolution in multiple myeloma — opportunities for precision medicine
Nature Reviews Clinical Oncology (2022)